Former Novartis worker nabs unfair dismissal award; FDA hands J&J CRL over antipsychotic;

@FiercePharma: Phibro records strong sales growth despite industry shift from antibiotics. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Alexion expanding in Ireland. Will spend $506M on its first biologics plant outside of U.S. News from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Endo plots a relaunch of Auxilium's ED med, complete with new salesforce and DTC. FiercePharmaMarketing report | Follow @CarlyHFierce

> An Irish court has awarded a former Novartis ($NVS) employee €40,000 for unfair dismissal. More

> A couple is alleging that Pfizer ($PFE) unit Wyeth has for 30 years concealed the risk of serious allergic reactions to pain reliever Advil, claiming in a New York court that the drug melted off 80% of their daughter's skin. Report (sub. req.)

> The FDA has issued a complete response letter in response to Johnson & Johnson's ($JNJ) sNDA for the long-acting version of antipsychotic Invega Sustenna. More

> Biogen ($BIIB) has named Matt Griffiths as its Chief Information Officer. Release

Medical Device News

@FierceMedDev: FDA approves Roche's cancer diagnostic as a guide to use of Amgen, Lilly meds. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Lilly hopes new drug delivery R&D center will prove useful in osteoporosis, diabetes arenas. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Biogen's hot MS meds could push Pfizer off its CNS throne. Report | Follow @EmilyWFierce

> Glaucoma micro stent player Glaukos files to raise up to $86M in an IPO. Story

> Seattle hospital sues Olympus over duodenoscope devices tied to superbug outbreak. Article

Biotech News

@FierceBiotech: China's BeiGene banks $97M to get its cancer drugs into the clinic. Article | Follow @FierceBiotech

@JohnCFierce: No, the IPO flood won't float all boats. Gelesis scraps plans, for now, for a $52M IPO. More | Follow @JohnCFierce

> One of Takeda's big cancer bets flops in a Phase III lymphoma trial. Report

> Sanofi doubles down on Selecta collaboration, adding $300M in fresh incentives. Article

Pharma Marketing News

> Wrongfully fired rep needs a real job offer, judge tells Bayer. And fork over that back pay, stat. More

> Want to know a secret? Pharma's patient services are going to waste. News

> Can pharma + tech wearables be a match made in patient heaven? Report

> Lucky 7 diabetes meds to join blockbuster club by 2020. Story

> Endo plots a relaunch of Auxilium's ED med, complete with new salesforce and DTC. More

Biotech Research News

> Moderna tops CNBC's list of most disruptive new technologies. Item

> VCU scientist preps gene therapy/drug combo for PhI prostate cancer study. Story

> Garvan team spotlights role of rogue cells in autoimmune diseases. Article

> Swift setback: A preclinical success in hep B is followed by safety woes. News

> Biopharma companies jump into the big data stampede for genetic triggers of disease. Report

Diagnostics News

> Soon-Shiong reels in $100M for cancer genomics unit. Item

> FDA approves Roche's cancer diagnostic as a guide to use of Amgen, Lilly meds. Story

> Navidea scores $60M loan to broaden reach for Lymphoseek. Article

> HTG Molecular Diagnostics unveils $50M IPO for genomic profiling technology. More

> Adaptive Biotechnologies reels in $195M for immunosequencing tech. News

And Finally... Breast feeding may cut the risk of breast-cancer recurrence, a new study shows. More (sub. req.)

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.